LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to assess the overall response rate of LBH589 in
patients with relapsed or refractory Waldenstrom's Macroglobulinemia. LBH589 is a newly
discovered compound that has killed Waldenstrom cells in laboratory studies, however, it is
not known if LBH589 will show the same activity in people with Waldenstrom's
Macroglobulinemia. This drug has been used in research for the treatment of other types of
cancer, such as multiple myeloma.